近日,中国药物临床试验登记与信息公示平台显示,百济神州基于全面利益/风险评估,决定停止BGB-30813的临床开发,主动终止了一项正在进行的 I 期临床试验。截图来源:药物临床试验登记与信息公示平台BGB-30813 是一款 DGKζ 抑制剂,于 23 年 6 月首次启动 I 期临床试验(NCT05904496/CTR20233404),旨在评估BGB-30813单药治疗或与抗 PD-1 单克隆...
Source Link近日,中国药物临床试验登记与信息公示平台显示,百济神州基于全面利益/风险评估,决定停止BGB-30813的临床开发,主动终止了一项正在进行的 I 期临床试验。截图来源:药物临床试验登记与信息公示平台BGB-30813 是一款 DGKζ 抑制剂,于 23 年 6 月首次启动 I 期临床试验(NCT05904496/CTR20233404),旨在评估BGB-30813单药治疗或与抗 PD-1 单克隆...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.